---

---

tags : Treatment    crawled date : 2023 - 01 - 04   

save search

---

Global Type 2 Diabetes Treatment Market Outlook Report 2022-2023 & 2027: Patent Cliff, Oral Antidiabetics, and Growing Focus on Accessibility and Affordability of Medicine Bolsters Growth
Published: 2023-01-04 (Crawled : 23:00) - prnewswire.com
AZNCF | $140.15 3.58% -4.19% 560 |

Health Technology

| -1.98% | O: -0.93% H: 3.08% C: 3.08%
NVO | News | $124.53 0.88% 0.19% 2.5M |

Health Technology

| -8.95% | O: -0.89% H: 1.18% C: 0.52%
NVS | News | $93.08 -0.13% 0.13% 1.1M |

Health Technology

| 1.35% | O: -0.85% H: 0.2% C: -0.29%
JNJ | News | $144.77 0.22% 0.4% 130K |

Health Technology

| -19.63% | O: -0.62% H: 0.54% C: -0.12%
SNY | News | $46.11 0.68% 0.7% 3.5M |

Health Technology

| -6.38% | O: -3.07% H: 0.0% C: 0.0%
AZN | $68.53 0.39% 0.39% 4.3K |

Health Technology

| -1.78% | O: -0.49% H: 1.65% C: 0.94%
treatment patent global report growing diabetes growth market

---

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant
Published: 2023-01-04 (Crawled : 15:00) - biospace.com/
JSPR | $23.82 -1.45% -2.0% 72K |

| 769.34% | O: -7.3% H: 1.57% C: -15.75%
treatment designation drug therapeutics

---

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes - January 4, 2023
Published: 2023-01-04 (Crawled : 14:20) - biospace.com/
ORMP | $2.33 -2.92% -2.78% 150K |

Health Technology

| -81.21% | O: 2.34% H: 4.41% C: 0.32%
treatment patent granted diabetes therapy insulin

---

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
Published: 2023-01-04 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M |

Health Technology

| 2.47% | O: 0.01% H: 0.13% C: -0.03%
treatment lupus trial therapeutics phase 2

---

Discovery Behavioral Health Wraps 2022 With Acquisitions of Leading Treatment Centers and Expansion into Major Markets, Executive Appointments, and Launch of DiscoveryMD
Published: 2023-01-04 (Crawled : 13:20) - prnewswire.com
FNCTF | News | $11.0354 -0.83% -20.84% 34K |

Communications

| Email alert Add to watchlist
treatment expansion acquisitions health

---

Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Published: 2023-01-04 (Crawled : 13:20) - globenewswire.com
FBIO | $1.77 0.57% 1.68% 250K |

Health Technology

| 170.77% | O: 6.15% H: 2.9% C: 1.45%
CKPT | $1.67 -1.18% -1.81% 1 |

Health Technology

| -72.48% | O: 3.75% H: 15.7% C: 4.55%
treatment fda application license therapeutics cell carcinoma cosibelimab

---

Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Published: 2023-01-04 (Crawled : 13:00) - biospace.com/
BCYC | $21.82 -0.5% -0.27% 440K |

Health Technology

| -26.9% | O: 4.13% H: 0.0% C: -1.41%
bt8009 treatment fda designation granted therapeutics bicycle cancer fast track designation

---

Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient Populations
Published: 2023-01-04 (Crawled : 12:00) - globenewswire.com
ROIV | $10.44 -2.52% -2.49% 3.3M |

Manufacturing

| 46.01% | O: 4.2% H: 2.15% C: 1.48%
rvt-3101 treatment global biomarker positive study phase 2b ulcerative colitis

---

Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
Published: 2023-01-04 (Crawled : 12:00) - globenewswire.com
CING M | $0.8518 5.16% 8.16% 49 |

| -20.59% | O: -1.96% H: 6.99% C: 2.0%
treatment adhd study

---

Hair loss treatment products market size to grow by USD 2,216.5 million, growth opportunities led by Church & Dwight Co Inc, Cipla Ltd, Costco Wholesale Corp - Technavio
Published: 2023-01-04 (Crawled : 09:00) - prnewswire.com
UL | $46.69 0.47% 0.84% 4.8M |

Consumer Non-Durables

| -7.49% | O: 0.52% H: 0.46% C: 0.16%
JNJ | News | $144.77 0.22% 0.4% 130K |

Health Technology

| -18.76% | O: 0.39% H: 0.73% C: 0.69%
treatment growth market

---

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
Published: 2022-12-28 (Crawled : 01:00) - globenewswire.com
ACST | $3.1899 -4.78% -1.2% 17K |

Health Technology

| 17.03% | O: 5.11% H: 12.06% C: 5.68%
gtx-102 treatment drug candidate topline study

---

Gainers vs Losers

57%

43%

Top 10 Gainers

INVO | $1.82 139.47% 49.67% 1.4M |

Health Technology

WISA 4 | $9.25 51.64% 34.27% 64M |

Electronic Technology

HOLO | $2.24 -5.49% 27.74% 7.7M |

SRFM 4 | $0.3859 -12.3% 23.84% 660K |

n/a

CTM | $0.2201 -2.31% 22.67% 48K |

n/a

VIAO | $0.262 0.77% 16.03% 14M |

Electronic Technology

DXF | $0.2708 -5.71% 14.48% 190K |

Finance

GRFX | $0.2159 -10.04% 12.55% 5.9K |

n/a

BHIL | $0.1722 -3.8% 12.08% 290K |

Agriculture, Forestry, Fishing ...

MCW 4 | $6.49 -1.22% 10.94% 6 |

Professional, Scientific, and T...

---

Your saved searches

---